European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

European Union - English - EMA (European Medicines Agency)

intervet international b.v - fluralaner - ectoparasiticides for systemic use, isoxazolines - dogs; cats - dogs:- for the treatment of tick and flea infestations;the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad).- for the treatment of demodicosis caused by demodex canis;- for the treatment of sarcoptic mange (sarcoptes scabiei var. canis) infestation.- for reduction of the risk of infection with babesia canis canis via transmission by dermacentor reticulatus. [chewable tablets only]cats:- for the treatment of tick and flea infestations;the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad).- for the treatment of infestations with ear mites (otodectes cynotis).

European Union - English - EMA (European Medicines Agency)

merial - bluetongue virus serotype 8 antigen - immunologicals for ovidae, immunologicals for bovidae - sheep; cattle - active immunisation of sheep and cattle to prevent viraemia* and to reduce clinical signs caused by bluetongue virus serotype 8.*(below the level of detection by the validated rt-pcr method at 3.14log10 rna copies/ml, indicating no infectious virus transmission).onset of immunity has been demonstrated 3 weeks after the primary vaccination course.the duration of immunity for cattle and sheep is 1 year after the primary vaccination course.the duration of immunity is not yet fully established in cattle or sheep, although interim results of ongoing studies demonstrate that the duration is at least 6 months after the primary vaccination course in sheep.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner - isoxazolines, ectoparasiticides for systemic use - dogs - treatment of flea infestation in dogs (ctenocephalides felis and c. canis)  for at least 5 weeks. the product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad).treatment of tick infestation in dogs (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus). one treatment kills ticks for up to one month.fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance. treatment of demodicosis (caused by demodex canis).treatment of sarcoptic mange (caused by sarcoptes scabiei var. canis).

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - afoxolaner, milbemycin oxime - endectocides, antiparasitic products, insecticides and repellents, milbemycin oxime, combinations - dogs - for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease (dirofilaria immitis larvae), angiostrongylosis (reduction in level of immature adults (l5) and adults of angiostrongylus vasorum), thelaziosis (adult thelazia callipaeda) and/or treatment of gastrointestinal nematode infestations is indicated.treatment of flea infestations (ctenocephalides felis and c. canis) in dogs for 5 weeks. treatment of tick infestations (dermacentor reticulatus, ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus) in dogs for 4 weeks.fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.treatment of infestations with adult gastrointestinal nematodes of the following species: roundworms (toxocara canis and toxascaris leonina), hookworms (ancylostoma caninum, ancylostoma braziliense and ancylostoma ceylanicum) and whipworm (trichuris vulpis). treatment of demodicosis (caused by demodex canis). treatment of sarcoptic mange (caused by sarcoptes scabiei var. canis). prevention of heartworm disease (dirofilaria immitis larvae) with monthly administration. prevention of angiostrongylosis (by reduction of the level of infection with immature adult (l5) and adult stages of angiostrongylus vasorum) with monthly administration.prevention of establishment of thelaziosis (adult thelazia callipaeda eyeworm infection) with monthly administration.

European Union - English - EMA (European Medicines Agency)

pfizer limited  - metaflumizone, amitraz - ectoparasiticides for topical use, incl. insecticides - dogs - for the treatment and prevention of infestations by fleas (ctenocephalides canis and c. felis), and ticks (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus and dermacentor variabilis), and treatment of demodicosis (caused by demodex spp.) and lice (trichodectes canis) in dogs.the veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (fad).

European Union - English - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs.onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and chlamydophila felis components.the duration of immunity is 1 year after the last (re-)vaccination.

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - cats - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs.onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components.the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer / recombinant type-d pasteurella-multocida toxin (pmtr) - immunologicals - pigs (gilts and sows) - for the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with bordetella-bronchiseptica and pasteurella-multocida infections during the fattening period. challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - sarolaner - ectoparasiticides for systemic use - dogs - for the treatment of tick infestations (dermacentor reticulatus, ixodes hexagonus, ixodes ricinus and rhipicephalus sanguineus). the veterinary medicinal product has immediate and persistent tick killing activity for at least 5 weeks.for the treatment of flea infestations (ctenocephalides felis and ctenocephalides canis). the veterinary medicinal product has immediate and persistent flea killing activity against new infestations for at least 5 weeks. the veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (fad).for the treatment of sarcoptic mange (sarcoptes scabiei).for the treatment of ear mite infestations (otodectes cynotis).for the treatment of demodicosis (demodex canis).fleas and ticks must attach to the host and commence feeding in order to be exposed to the active substance.